Beacon Financial Group Sells 323 Shares of Cencora, Inc. (NYSE:COR)

Beacon Financial Group lessened its position in shares of Cencora, Inc. (NYSE:COR) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,375 shares of the company’s stock after selling 323 shares during the period. Beacon Financial Group’s holdings in Cencora were worth $2,556,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of COR. Valeo Financial Advisors LLC increased its holdings in shares of Cencora by 5.0% in the third quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock worth $370,000 after purchasing an additional 79 shares during the period. Exchange Traded Concepts LLC grew its position in Cencora by 41.6% during the third quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company’s stock worth $1,201,000 after buying an additional 1,568 shares in the last quarter. CX Institutional increased its stake in Cencora by 8.0% in the 3rd quarter. CX Institutional now owns 8,868 shares of the company’s stock worth $1,996,000 after acquiring an additional 654 shares during the last quarter. Occidental Asset Management LLC raised its holdings in shares of Cencora by 4.3% in the 3rd quarter. Occidental Asset Management LLC now owns 16,193 shares of the company’s stock valued at $3,645,000 after acquiring an additional 665 shares in the last quarter. Finally, NBC Securities Inc. boosted its position in shares of Cencora by 3.9% during the 3rd quarter. NBC Securities Inc. now owns 5,680 shares of the company’s stock valued at $1,278,000 after acquiring an additional 211 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,187 shares of company stock valued at $17,790,912. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Robert W. Baird upped their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. UBS Group boosted their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Finally, Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $277.90.

Cencora Price Performance

Shares of NYSE:COR opened at $246.86 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $47.71 billion, a PE ratio of 35.11, a PEG ratio of 1.49 and a beta of 0.49. The company’s fifty day moving average is $238.86 and its 200 day moving average is $237.03. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts anticipate that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.89%. Cencora’s payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.